News

CATEGORIES

CONTACT THE MEDIA TEAM

If you are a journalist with questions or an interview or media request, please do not hesitate to contact us.
CONTACT US

Archive

see all

Recent Posts

Matteo Pellegrino

Recent Posts by Matteo Pellegrino:

AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site

by Matteo Pellegrino Published on 8/20/21 10:30 AM News

AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site
(COPENHAGEN), August 20, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site. This multipurpose facility will allow AGC Biologics to increase its capacity and space to accommodate new and existing clients’ needs. 
Learn More

AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site

by Matteo Pellegrino Published on 8/9/21 10:00 PM News

(LONGMONT), August 9, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new leadership appointment to oversee strategic development and operational excellence in large-scale C&GT production at its Longmont site in Colorado. Effective August 9, 2021, Tony Fraij will join the Longmont team as General Manager/Site Head.
Learn More

AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings

by Matteo Pellegrino Published on 8/5/21 9:00 AM News

AGC Biologics acquires Longmont, Colorado facility to expand its global footprint and increase its C&GT process development and GMP capacity 
 
(SEATTLE), August 5, 2021 – AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the finalization of the purchase of a state-of-the-art commercial manufacturing facility in Longmont, Colorado, USA. The facility, previously owned by Novartis Gene Therapies, will provide AGC Biologics with significant additional capacity and space to continue to expand its global end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers.
 
Learn More

AGC Biologics Appoints Kevin Ingham as the new General Manager/Site Head of their Seattle, Washington Site

by Matteo Pellegrino Published on 8/2/21 11:00 AM News

(SEATTLE), August 2, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the strategic development and operational excellence in clinical and commercial biologics production at its Seattle, Washington site. Effective August 2, 2021, Kevin Ingham will join the Seattle team as the General Manager/Site Head. 
Learn More

AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings

by Matteo Pellegrino Published on 7/1/21 9:00 AM News

(SEATTLE), July 1, 2021 -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement for a state-of-the-art Cell and Gene Therapy commercial manufacturing facility in Longmont, Colorado, currently owned by Novartis Gene Therapies. Once the transaction closes, pending final due diligence, the facility will equip AGC Biologics with significant additional capacity and space to continue to expand its end-to-end Cell and Gene Therapy (C&GT) offering, ensuring security of supply for current and future C&GT customers. This facility is only 16 miles from AGC Biologics’ state-of-the-art large-scale stainless steel mammalian facility in Boulder, CO.dronegenuity-Longmont-CO-017-1
Learn More

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III

by Matteo Pellegrino Published on 6/23/21 5:30 AM News

TEL AVIV, Israel and SEATTLE, Wash. June 21, 2021 – Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need, and AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to manufacture CM-101, a Phase II investigational drug targeting Primary Sclerosing Cholangitis, Systemic Sclerosis, and Liver Fibrosis MoA (NASH). Under terms of the agreement, the companies will work together to optimize, upscale and lock the CM-101 manufacturing process towards its testing in pivotal studies while AGC Biologics will manufacture the clinical trial materials at its site in Copenhagen, to support phase II/III clinical testing and launch readiness.
Learn More
All Posts
Follow Us
Join us on LinkedIn Follow us on Twitter
Content not found